Advocating the potential for a single dose of #SARSCoV2 vaccines @zeynep @michaelmina_lab https://www.nytimes.com/2020/12/18/opinion/coronavirus-vaccine-doses.html?action=click&module=Opinion&pgtype=Homepage …
The points for studying this are good but the public message to many for skipping the 2nd dose is troubling when we don't really know what protection that provides
-
Show this thread
-
I’d also say proposing to test it in HCW is a no sale. They’ve been so traumatized the last 10 months asking this particular group to give up a schedule with 95% efficacy for something unknown, when it’s the first thing we have to directly protect us, feels bad
1 reply 1 retweet 16 likes -
Absolutely agree it should be voluntary. However I did hear from many HCW who said they would volunteer. This should clearly be an adaptive trial, with frequent monitoring. We should be able to pick up signals quickly. It’s a question of proper attention and resource allocation.
2 replies 1 retweet 5 likes -
Of course. Thx. Also curious why HCW were proposed to start. Is seems the argument is they are no longer at increased risk (which I find debatable) & if that’s the case why not also offer it to low risk people who wouldn’t get vaccine for a while otherwise, If risk is similar?
1 reply 0 retweets 0 likes -
I think the latter is a very good option as well!
1 reply 0 retweets 2 likes -
I’m also skeptical of the suggestion of HCWs for RCT. The same factors that make them low risk (good infection control in most health care facilities) would make the trial take longer to deliver results. If the goal is fast results, this doesn’t seem like the right population.
1 reply 0 retweets 3 likes -
Good points. That may argue for offering vax+vax/placebo to a population who’d get no vaccine at this point. Also following up systematically with people who sadly will miss anyway—as happens so much. Bonus, we could vaccinate them after finding them.
1 reply 0 retweets 2 likes -
Analyzing those who miss their second dose after usual attempts to contact them (although by definition, this group may be hard to contact for a follow up study) is where observational epidemiology could shine.
@UNCpublichealth has a great pharmacoepi group: I’ll ask if plans3 replies 0 retweets 5 likes
Excellent! Understanding the results from the (unfortunate but always happens) group would have multiple benefits! Real-world data, evidence-driven allocation of resources plus those people get a followup. UK RECOVERY had a similar logic and gave us dexa.
Loading seems to be taking a while.
Twitter may be over capacity or experiencing a momentary hiccup. Try again or visit Twitter Status for more information.